Keros Therapeutics, Inc. (KROS) Financials
KROS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 370.0 million | 37.8 million |
2023-09-30 | 326.2 million | 30.4 million |
2023-06-30 | 356.3 million | 30.0 million |
2023-03-31 | 384.4 million | 29.5 million |
KROS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -26.0 million | 7.3 million |
2023-09-30 | -34.5 million | 8.7 million |
2023-06-30 | -31.1 million | 7.0 million |
2023-03-31 | -35.3 million | 5.7 million |
KROS Net Income
No data available :(
KROS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 331.1 million | - | 14.4 million |
2023-09-30 | 287.9 million | - | 14.3 million |
2023-06-30 | 322.0 million | - | 14.0 million |
2023-03-31 | 351.4 million | - | 14.0 million |
KROS Shares Outstanding
KROS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 541000 | 37.5 million | 9.1 million | - |
2023-09-30 | 550000 | 34.1 million | 9.1 million | - |
2023-06-30 | 311000 | 32.5 million | 8.8 million | - |
2023-03-31 | 1.1 million | 31.1 million | 7.8 million | - |
KROS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 143000 | 247000 |
2023-09-30 | 8000 | 551000 |
2023-06-30 | - | 545000 |
2023-03-31 | - | 689000 |
KROS
Price: $57.72
52 week price:
Earnings Per Share: -5.20 USD
P/E Ratio: -11.92
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 412500
Market Capitalization: 2.1 billion